Propanc Biopharma (NASDAQ: PPCB) has announced plans to purchase $100 million worth of Ethereum (ETH) over the next 12 months. This move is part of the company's diversification strategy aimed at optimizing asset allocation. The biopharmaceutical firm intends to support its operations in drug development, asset acquisitions, and cryptocurrency ventures through this investment.